Aclarion, Inc. (ACON) saw a significant premarket surge on Monday following the announcement of a commercial partnership with Scripps Health in San Diego, California. This agreement will bring Aclarion’s Nociscan diagnostic tool to Southern California and will be accessible to leading spine specialists at Scripps Green and throughout the Scripps Health network.
Scripps Health, a non-profit healthcare system, operates five hospitals and 19 outpatient facilities, serving approximately half a million patients annually with the support of 2,600 affiliated physicians. This partnership represents a major step forward for Aclarion.
“We are pleased to bring Nociscan to Scripps Health and the millions of people throughout Southern California,” said Ryan Bond, Chief Strategy Officer of Aclarion. “Dr. Eastlack and his colleagues will now be able to utilize Nociscan in clinic and within on-going research trials, both of which are vitally important to their mission of advancing spine care.”
This announcement comes after Aclarion secured funding last month for its CLARITY trial, which focuses on its Nociscan diagnostic tool. Furthermore, Northwestern Medicine was identified as the initial site for the pivotal CLARITY trial, designed to demonstrate Nociscan’s clinical and economic advantages in spine surgery.
Price Action: As of the last check on Monday, ACON shares were trading up 84.8% at $6.19 premarket.
